PO69 | INCIDENTAL CANCER DETECTED DURING EMERGENCY DIAGNOSTIC WORK-UP FOR ACUTE PULMONARY EMBOLISM: A RETROSPECTIVE COHORT STUDY
L. Mocerino1, A. Casoria2, S. Mangiacapra2, M. Amitrano2, V. Bassi3, A. Tufano1 | 1Department of Clinical Medicine and Surgery. Federico II University of Naples, Italy; 2Internal Medicine Unit, Moscati Hospital, Avellino, Italy; 3U.O.C. di Medicina Generale e Lungodegenza, San Giovanni Bosco Hospital, ASL; Na1 Centro, Naples, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background. Pulmonary embolism (PE) may represent the first clinical manifestation of an occult malignancy. The prevalence of incidentally detected cancer during emergency department (ED) diagnostic work-up for acute PE remains incompletely characterized, particularly in the presence of provoking factors.
Objectives. To estimate the prevalence of incidental cancer detected during ED investigations for acute PE, to describe the cancer types, and to distinguish between provoked and unprovoked PE cases.
Methods. We conducted a retrospective observational study including 93 consecutive patients admitted with acute PE. Incidental cancer was defined as a previously unknown malignancy detected during diagnostic investigations performed for PE in the ED. PE was classified as provoked or unprovoked based on the presence of identifiable transient or persistent risk factors.
Results. Incidental cancer was detected in 21 of 93 patients (22.6%). Lung cancer was the most frequent malignancy (33.3%), followed by colorectal cancer (23.8%). Notably, 19 of 21 incidental cancers (90.5%) occurred in patients with unprovoked PE, whereas only 2 cases (9.5%) were observed among patients with provoked PE. The prevalence of incidental cancer was 32.8% in unprovoked PE compared with 5.7% in provoked PE. Median age was 75 years (IQR 65–81), and 53.8% of patients were female.
Conclusions. In this cohort, nearly one quarter of patients presenting with acute PE had an incidentally detected malignancy during PE work-up, with the vast majority occurring in unprovoked PE setting. These findings reinforce the role of unprovoked PE as a potential early marker of occult cancer and support careful evaluation of incidental imaging findings in this population.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- ICTHIC 2026, OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, OC08 | A SILK-BASED 3D BONE MARROW MODEL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO08 | NEXT-GENERATION THROMBOLYTICS: ENGINEERING STREPTOKINASE FOR ENHANCED ACTIVITY AND REDUCED IMMUNOGENICITY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- ICTHIC 2026, PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
